Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 4/2012

01-11-2012

Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention

Authors: Yiding Li, Bee-Choo Tai, Winnie Sia, Qian-Hui Phua, Mark A. Richards, Adrian Low, Koo-Hui Chan, Swee-Guan Teo, Tiong-Beng Sim, Chi-Hang Lee, Matthew T. Roe, Tiong-Cheng Yeo, Huay-Cheem Tan, Mark Y. Chan

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2012

Login to get access

Abstract

Pretreatment with 60 mg of prasugrel is more effective than 300 mg of clopidogrel in reducing thrombotic complications with primary percutaneous coronary intervention (PCI). We compared angiographic outcomes and platelet reactivity between treatment with 60 mg of prasugrel and 600 mg of clopidogrel administered before primary PCI. In this single centre non-randomized study, 65 consecutive Asian patients with ST-elevation myocardial infarction (STEMI) received 60 mg of prasugrel before primary PCI. The pre- and post-PCI corrected thrombolysis in myocardial infarction frame count (CTFC) and the 8-h post-treatment platelet vasodilator-stimulated phosphoprotein (VASP) index was compared with a matched historical Asian STEMI cohort (n = 65) receiving 600 mg of clopidogrel pretreatment. Comparing the prasugrel and clopidogrel groups, the mean age was 54.1 ± 10.2 versus 55.5 ± 11.8 years, P = 0.238, and the mean body mass index was 24.6 ± 2.0 versus 24.7 ± 2.8 kg m−2, P = 0.393. The mean pre-PCI CTFC was 82.1 ± 30.2 versus 86.1 ± 27.6, P = 0.045, and the mean post-PCI CTFC was 21.1 ± 13.9 versus 20.1 ± 9.2, P = 0.309. Pre-PCI coronary thrombi were visualised in 6.3 versus 18.1 %, P = 0.038. The median VASP index was 22.2 ± 24.5 versus 70.5 ± 17.5 %, P < 0.001, and high on-treatment platelet reactivity (VASP index > 50 %) was observed in 13.8 versus 84.3 %, P = 0.001. Rescue intracoronary glycoprotein inhibitors were administered to 29.7 versus 51.0 %, P = 0.018, respectively. Treatment with 60 mg of prasugrel before primary PCI was associated with lower platelet reactivity, a modest trend towards better pre-PCI angiographic outcomes, less pre-PCI coronary thrombi and less rescue glycoprotein inhibitor use compared with 600 mg of clopidogrel. The very high frequency of high on-clopidogrel platelet reactivity with 600 mg of clopidogrel in this Asian STEMI cohort deserves further study.
Literature
1.
go back to reference Sabatine MS, Cannon CP, Gibson CM et al (2005) Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics. The PCI-CLARITY study. J Am Med Assoc 294(10):1224–1232CrossRef Sabatine MS, Cannon CP, Gibson CM et al (2005) Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics. The PCI-CLARITY study. J Am Med Assoc 294(10):1224–1232CrossRef
2.
go back to reference Hasegawa M, Sugidachi A, Ogawa T et al (2005) Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost 94:593–598PubMed Hasegawa M, Sugidachi A, Ogawa T et al (2005) Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost 94:593–598PubMed
3.
go back to reference Montalescot G, Wiviott SD, Braunwald E et al (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON–TIMI 38): double-blind, randomised controlled trial. Lancet 373:723–731PubMedCrossRef Montalescot G, Wiviott SD, Braunwald E et al (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON–TIMI 38): double-blind, randomised controlled trial. Lancet 373:723–731PubMedCrossRef
4.
go back to reference Patti G, Barczi G, Orlic D et al (2011) Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. J Am Coll Cardiol 58:1592–1599PubMedCrossRef Patti G, Barczi G, Orlic D et al (2011) Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. J Am Coll Cardiol 58:1592–1599PubMedCrossRef
5.
go back to reference Small DS, Payne CD, Kothare P et al (2010) Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. Clin Ther 32:365–379PubMedCrossRef Small DS, Payne CD, Kothare P et al (2010) Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. Clin Ther 32:365–379PubMedCrossRef
6.
go back to reference van Werkum JW, van der Stelt CA, Seesing TH et al (2007) The flow cytometric VASP assay can be used to determine the effectiveness of clopidogrel in patients treated with abciximab. J Thromb Haemost 5:881–883PubMedCrossRef van Werkum JW, van der Stelt CA, Seesing TH et al (2007) The flow cytometric VASP assay can be used to determine the effectiveness of clopidogrel in patients treated with abciximab. J Thromb Haemost 5:881–883PubMedCrossRef
7.
go back to reference Gibson CM, Cannon CP, Daley WL et al (1996) TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93:879–888PubMedCrossRef Gibson CM, Cannon CP, Daley WL et al (1996) TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93:879–888PubMedCrossRef
8.
go back to reference Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919–933PubMedCrossRef Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919–933PubMedCrossRef
9.
go back to reference Chan MY, Sun JL, Wang TY et al (2010) Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. Am Heart J 160:1056–1064, 1064. e2 Chan MY, Sun JL, Wang TY et al (2010) Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. Am Heart J 160:1056–1064, 1064. e2
10.
go back to reference Montalescot G, Sideris G, Cohen R et al (2010) Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 103:213–223PubMedCrossRef Montalescot G, Sideris G, Cohen R et al (2010) Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 103:213–223PubMedCrossRef
11.
go back to reference Fernando H, Dart AM, Peter K et al (2011) Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thromb Haemost 105:933–944PubMedCrossRef Fernando H, Dart AM, Peter K et al (2011) Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thromb Haemost 105:933–944PubMedCrossRef
12.
go back to reference O’Donoghue M, Antman EM, Braunwald E et al (2009) The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol 54:678–685PubMedCrossRef O’Donoghue M, Antman EM, Braunwald E et al (2009) The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol 54:678–685PubMedCrossRef
13.
go back to reference Wiviott SD, Trenk D, Frelinger AL et al (2007) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116:2923–2932PubMedCrossRef Wiviott SD, Trenk D, Frelinger AL et al (2007) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116:2923–2932PubMedCrossRef
14.
go back to reference Bonello L, Pansieri M, Mancini J et al (2011) High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 58:467–473PubMedCrossRef Bonello L, Pansieri M, Mancini J et al (2011) High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 58:467–473PubMedCrossRef
15.
go back to reference Man M, Farmen M, Dumaual C et al (2010) Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol 50:929–940PubMedCrossRef Man M, Farmen M, Dumaual C et al (2010) Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol 50:929–940PubMedCrossRef
16.
go back to reference Chan MY, Tan K, Tan H-C et al (2012) Functional significance and differential prevalence of CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Pharmacogenomics 13:533–542PubMedCrossRef Chan MY, Tan K, Tan H-C et al (2012) Functional significance and differential prevalence of CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Pharmacogenomics 13:533–542PubMedCrossRef
Metadata
Title
Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention
Authors
Yiding Li
Bee-Choo Tai
Winnie Sia
Qian-Hui Phua
Mark A. Richards
Adrian Low
Koo-Hui Chan
Swee-Guan Teo
Tiong-Beng Sim
Chi-Hang Lee
Matthew T. Roe
Tiong-Cheng Yeo
Huay-Cheem Tan
Mark Y. Chan
Publication date
01-11-2012
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2012
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-012-0782-y

Other articles of this Issue 4/2012

Journal of Thrombosis and Thrombolysis 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine